.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 9,422,223

« Back to Dashboard

Claims for Patent: 9,422,223

Title:Compounds and methods for delivery of prostacyclin analogs
Abstract: This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.
Inventor(s): Phares; Ken (Chapel Hill, NC), Mottola; David (Cary, NC), Jeffs; Roger (Chapel Hill, NC)
Assignee: United Therapeutics Corporation (Silver Spring, MD)
Application Number:14/881,379
Patent Claims: 1. An oral pharmaceutical formulation: comprising a treprostinil diethanolamine, which has an absolute bioavailability of at least 15% upon oral administration to a human subject, wherein said formulation when orally administered to the human subject a) provides a linear increase over 8 hours of a Cmax in a plasma of the human subject with a dose of at least 0.05 mg administered orally to the human subject and b) maintains a concentration of treprostinil in the plasma of the human subject of at least 50 pg/ml for at least 8 hours.

2. The oral pharmaceutical formulation of claim 1, wherein the absolute bioavailability of said treprostinil diethanolamine ranges from 21 to 25% upon oral administration to the human subject.

3. The oral pharmaceutical formulation of claim 1, wherein the oral bioavailability of the treprostinil diethanolamine is at least 50% greater than the oral bioavailability of treprostinil as free acid.

4. The oral pharmaceutical formulation of claim 1, wherein the oral bioavailability of the treprostinil diethanolamine is at least 100% greater than the oral bioavailability of treprostinil as free acid.

5. An oral pharmaceutical formulation: comprising a treprostinil diethanolamine, which has an absolute bioavailability of at least 15% upon oral administration to a human subject, wherein said formulation when orally administered to the human subject a) provides a linear increase over 8 hours of a AUCinf in a plasma of the human subject with a dose of at least 0.05 mg administered orally to the human subject and b) maintains a concentration of treprostinil in the plasma of the human subject of at least 50 pg/ml for at least 8 hours.

6. The oral pharmaceutical formulation of claim 5, wherein the absolute bioavailability of said treprostinil diethanolamine ranges from 21 to 25% upon oral administration to the human subject.

7. The oral pharmaceutical formulation of claim 5, wherein the oral bioavailability of the treprostinil diethanolamine is at least 50% greater than the oral bioavailability of treprostinil as free acid.

8. The oral pharmaceutical formulation of claim 5, wherein the oral bioavailability of the treprostinil diethanolamine is at least 100% greater than the oral bioavailability of treprostinil as free acid.

9. The oral pharmaceutical formulation of claim 1, wherein the formulation comprises 0.125 mg of the treprostinil diethanolamine.

10. The oral pharmaceutical formulation of claim 1, wherein the formulation comprises 0.25 mg of the treprostinil diethanolamine.

11. The oral pharmaceutical formulation of claim 1, wherein the formulation comprises 1 mg of the treprostinil diethanolamine.

12. The oral pharmaceutical formulation of claim 5, wherein the formulation comprises 0.125 mg of the treprostinil diethanolamine.

13. The oral pharmaceutical formulation of claim 5, wherein the formulation comprises 0.25 mg of the treprostinil diethanolamine.

14. The oral pharmaceutical formulation of claim 5, wherein the formulation comprises 1 mg of the treprostinil diethanolamine.

15. The oral pharmaceutical formulation of claim 1, wherein the dose is no more than 2 mg of the treprostinil diethanolamine.

16. The oral pharmaceutical formulation of claim 5, wherein the dose is no more than 2 mg of the treprostinil diethanolamine.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc